Screening of drug candidates can improve the success rate of new drug R&D, reduce R&D costs, and shorten the development cycle of innovative drugs. Our screening services include efficacy screening (in vivo and in vitro), bioavailability screening, metabolic screening, and early toxicity screening.
Technical Approaches
Molecular biology, enzymology, cytology, immunology, organ and tissue assays, animal studies
Service Areas
Cardiovascular diseases, cerebrovascular diseases, inflammatory & autoimmune diseases, metabolic diseases, musculoskeletal disorders, neurological & psychiatric disorders, oncology, nephropathy, hematological diseases, coagulation & hemostasis, ophthalmic disease models, vaccines, etc.
Bioavailability and Metabolic Screening (In Vivo & In Vitro)
Muridda conducts early-stage screening assays for bioavailability and metabolic profiles of small-molecule compounds and biological macromolecules, as well as early tissue distribution studies, to help clients rapidly identify and optimize drug candidates.
Technical Approaches
Immunoassays (ELISA), LC-MS/MS, HPLC, isotope labeling, bioassays
Service Areas
Compounds, biological macromolecules, traditional Chinese medicines, cell therapy products, gene therapy products
Early Toxicity Screening
Early-stage genotoxicity, acute toxicity, embryotoxicity, and cardiotoxicity assays allow rapid identification of drug candidates with lower toxicity from compound series.
Single and Repeated-Dose Toxicity Screening
Custom-designed, rapid, and highly efficient studies for accurate prediction of in vivo drug toxicity and target organs.
Can be performed in small and large animal models.
Genotoxicity Assays
Ames test, micronucleus test
Cardiotoxicity Assays
Langendorff isolated heart perfusion: ECG, LVP, cardiac papillary muscle action potential recording (APD30/APD90), patch clamp: hERG current assay
Reproductive Toxicity Assays
Whole embryo culture (WEC)